Ascites Market Report and Forecast 2023-2031

The global ascites market size attained a value of USD 2.07 billion in 2022. The market is anticipated to grow at a CAGR of 4.3% during the forecast period of 2023-2031 to attain a value of USD 3.02 billion by 2031.

Ascites Market: Introduction

Ascites is the abnormal accumulation of fluid in the peritoneal cavity, which is the space between the abdominal organs and the abdominal wall. It is a symptom rather than a disease itself and is often associated with underlying medical conditions that affect the liver, heart, kidneys, or other organs. Ascites can be classified as either transudative (caused by changes in pressure within blood vessels) or exudative (caused by inflammation or infection).

The most common cause of ascites is liver cirrhosis, accounting for approximately 80% of cases. Cirrhosis leads to increased pressure in the portal vein system (portal hypertension) and reduced production of albumin, a protein that helps maintain fluid balance within blood vessels. As a result, fluid leaks from blood vessels into the peritoneal cavity.

Other causes of ascites include:

1. Heart failure: Poor heart function can lead to fluid build-up throughout the body, including the peritoneal cavity.
2. Kidney disease: Nephrotic syndrome, a condition characterized by protein loss in the urine, can result in low blood protein levels and fluid accumulation in the abdomen.
3. Cancer: Tumours in the abdomen, such as ovarian or gastrointestinal cancers, can cause inflammation and fluid build-up, leading to exudative ascites.
4. Infection: Peritonitis, an infection of the peritoneal cavity, can lead to inflammation and fluid accumulation.
5. Pancreatitis: Inflammation of the pancreas can cause fluid to leak into the peritoneal cavity.
6. Hypoalbuminemia: Low blood levels of albumin due to malnutrition or liver disease can contribute to fluid accumulation in the abdomen.

In some cases, the underlying cause of ascites may be challenging to determine, requiring further diagnostic tests and evaluations by medical professionals. Treatment for ascites generally involves addressing the underlying cause and may include medications, lifestyle changes, or surgical interventions as appropriate.

Ascites Market Segmentations

The market can be categorised into treatment, diagnosis, route of administration, end user, and region.

Ascites Market Breakup by Treatment

• Medicinal Therapy
• Diuretics
• Antibiotics
• Surgery
• Paracentesis
• Others

Market Breakup by Diagnosis

• Ascites Ultrasound
• CT Scan
• MRI
• Blood Test
• Laparoscopy
• Angiography
• Others

Market Breakup by Route of Administration

• Oral
• Parenteral
• Others

Market Breakup by End User

• Hospitals & Clinics
• Research and Academic Laboratories
• Others

Market Breakup by Region

North America

• United States of America
• Canada

Europe

• United Kingdom
• Germany
• France
• Italy
• Others

Asia Pacific

• China
• Japan
• India
• ASEAN
• Australia
• Others

Latin America

• Brazil
• Argentina
• Mexico
• Others

Middle East and Africa

• Saudi Arabia
• United Arab Emirates
• Nigeria
• South Africa
• Others

Ascites Market Scenario

The global ascites market is driven by the increasing prevalence of underlying conditions that lead to ascites, such as liver cirrhosis, heart failure, kidney disease, and certain cancers. This market encompasses various aspects, including diagnostic tools, therapeutic interventions, and supportive care services aimed at managing ascites and its complications. The market is influenced by factors such as the aging population, advancements in diagnostic and treatment technologies, and increased awareness of liver diseases and other associated conditions.

Market Drivers

The ascites market is propelled by several factors, including the growing prevalence of liver cirrhosis and other underlying conditions responsible for ascites development. Additionally, the aging population, which is more susceptible to these conditions, contributes to the market's growth. Technological advancements in diagnostic tools, such as imaging modalities and laboratory tests, help detect ascites earlier and more accurately, further driving market growth. Furthermore, the development of novel therapeutic interventions, including new medications and minimally invasive procedures, offers improved treatment options for patients with ascites.

Market Challenges

Despite the growing demand for ascites management, the market faces certain challenges. The high cost of diagnostic tools and treatments may limit access to care, particularly in low- and middle-income countries. Furthermore, the shortage of specialized healthcare professionals, such as hepatologists and gastroenterologists, can hinder effective ascites management in some regions. Additionally, the complexity of managing ascites, especially in patients with advanced liver disease or other comorbidities, poses significant challenges to healthcare providers and patients alike.

Regional Analysis

Geographically, the global ascites market can be segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominates the market due to its advanced healthcare infrastructure, increased awareness of liver diseases, and the presence of key market players. Europe follows closely, while Asia-Pacific is anticipated to be the fastest-growing region due to the increasing prevalence of underlying conditions, improving healthcare infrastructure, and rising healthcare expenditures in the region.

Future Outlook

The ascites market is expected to continue growing in the coming years, primarily driven by the increasing prevalence of underlying conditions, advancements in diagnostic and treatment technologies, and improved access to healthcare services. As new technologies emerge and healthcare systems continue to evolve, the market may experience increased access to treatment and improved patient outcomes, resulting in a more robust and dynamic ascites market.

Key Players in the Global Ascites Market

The report gives an in-depth analysis of the key players involved in the ascites market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• Becton, Dickinson and Company
• BioVie Inc
• Sequana Medical NV
• Sanofi Inc
• F. Hoffmann-La Roche Ltd
• Teva Pharmaceutical Industries Ltd
• Novartis AG
• Sun Pharmaceutical Industries Ltd
• Merck & Co., Inc
• WOCKHARDT